Valneva SE (VALN) Gains from Investment Securities (2021 - 2026)
Valneva SE's (VALN) quarterly Gains from Investment Securities came in at -$1170.7 in Q1 2026, up 99.73% year-on-year from -$586.17 in Q1 2025, and up 99.93% quarter-over-quarter from -$1.7 million in Q3 2025.
Valneva SE (VALN) Gains from Investment Securities (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Gains from Investment Securities across 6 years of filings, most recently posting -$1170.7 for Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at -$1170.7, up 99.73% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.4 million (down 20.33% YoY), and the FY2024 annual result was -$1.7 million, down 24.15% from the prior year.
- Gains from Investment Securities came in at -$1170.7 for Q1 2026 at Valneva SE, up from -$1.7 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $699.0 million in Q3 2023 to a low of -$699.7 million in Q2 2023.
- The 5-year median for Gains from Investment Securities is -$352216.0 (2022), against an average of -$362552.2.
- Peak annual rise in Gains from Investment Securities reached 262688.54% in 2023, while the deepest fall reached 131047.09% in 2023.
- Valneva SE's Gains from Investment Securities stood at $946789.6 in 2022, then slumped by 136.71% to -$347528.6 in 2023, then soared by 104.0% to $13891.7 in 2024, then tumbled by 12681.13% to -$1.7 million in 2025, then soared by 99.93% to -$1170.7 in 2026.
- The last three Gains from Investment Securities figures came in at -$1170.7 (Q1 2026), -$1.7 million (Q3 2025), and -$185641.4 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,170.75 |
| Mar 31, 2026 | -1,170.75 |
| Sep 30, 2025 | -1.75 Mn |
| Sep 30, 2025 | -1.75 Mn |
| Jun 30, 2025 | -185,641.39 |
| Jun 30, 2025 | -185,641.39 |
| Mar 31, 2025 | -432,324.50 |
| Mar 31, 2025 | -432,324.50 |
| Dec 31, 2024 | 13,891.74 |
| Dec 31, 2024 | 13,891.74 |
| Sep 30, 2024 | -496,395.22 |
| Sep 30, 2024 | -496,395.22 |
| Jun 30, 2024 | -1.05 Mn |
| Jun 30, 2024 | -1.05 Mn |
| Mar 31, 2024 | -140,140.67 |
| Mar 31, 2024 | -140,140.67 |
| Dec 31, 2023 | -347,528.59 |
| Dec 31, 2023 | -347,528.59 |
| Sep 30, 2023 | 698.97 Mn |
| Sep 30, 2023 | 698.97 Mn |